NO972913L - Rekombinante IL-5 antagonister anvendelige ved behandling av IL-5 betingete forstyrrelser - Google Patents

Rekombinante IL-5 antagonister anvendelige ved behandling av IL-5 betingete forstyrrelser

Info

Publication number: NO972913L
Authority: NO; Norway
Prior art keywords: treatment; pct; recombinant; antagonists useful; conditioned
Prior art date: 1994-12-23

Application number

NO972913A

Other languages

English (en)

Other versions

NO324181B1 (no

NO972913D0 (no

Inventor

Robert S Ames

Edward Robert Appelbaum

Irwin M Chaiken

Richard M Cook

Mitchell Stuart Gross

Stephen Dudley Holmes

Lynette Jane Mcmillan

Timothy Wayne Theisen

Original Assignee

Smithkline Beecham Corp

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-23

Filing date

1997-06-20

Publication date

1997-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO972913(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-06 Priority claimed from US08/467,420 external-priority patent/US5683892A/en

1997-06-20 Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp

1997-06-20 Publication of NO972913D0 publication Critical patent/NO972913D0/no

1997-08-19 Publication of NO972913L publication Critical patent/NO972913L/no

2007-09-03 Publication of NO324181B1 publication Critical patent/NO324181B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Zoology (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)

NO19972913A 1994-12-23 1997-06-20 Monoklonalt antistoff spesifikt for human IL-5 og fragmenter derav, hybridoma cellelinjer, endret antistoff, immunolglobulin-tungkjede-komplementaritetsbestemmende region, nukleinsyremolekyl, kimaert antistoff, farmasoytisk preparat omfattende endret antistoff, anvendelse av antistoff, isolert nukleinsyresekvens, rekombinant plasmid, vertcelle, fremgangsmate for a fremstille et endret antistoff og metoder for a bestemme human IL-50. NO324181B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US36313194A	1994-12-23	1994-12-23
US08/467,420 US5683892A (en)	1994-12-23	1995-06-06	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en)	1994-12-23	1995-06-06	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en)	1994-12-23	1995-12-22	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (3)

Publication Number	Publication Date
NO972913D0 NO972913D0 (no)	1997-06-20
NO972913L true NO972913L (no)	1997-08-19
NO324181B1 NO324181B1 (no)	2007-09-03

Family

ID=27408594

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19972913A NO324181B1 (no)	1994-12-23	1997-06-20	Monoklonalt antistoff spesifikt for human IL-5 og fragmenter derav, hybridoma cellelinjer, endret antistoff, immunolglobulin-tungkjede-komplementaritetsbestemmende region, nukleinsyremolekyl, kimaert antistoff, farmasoytisk preparat omfattende endret antistoff, anvendelse av antistoff, isolert nukleinsyresekvens, rekombinant plasmid, vertcelle, fremgangsmate for a fremstille et endret antistoff og metoder for a bestemme human IL-50.
NO2015027C NO2015027I2 (no)	1994-12-23	2015-12-18	Mepolizumab

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2015027C NO2015027I2 (no)	1994-12-23	2015-12-18	Mepolizumab

Country Status (21)

Country	Link
US (1)	US6129913A (no)
EP (1)	EP0800536B1 (no)
JP (2)	JP2001523083A (no)
CN (1)	CN100391977C (no)
AT (1)	ATE346867T1 (no)
AU (1)	AU708951B2 (no)
BR (1)	BR9510499B1 (no)
CA (1)	CA2208503C (no)
CZ (1)	CZ297045B6 (no)
DE (1)	DE69535319T2 (no)
DK (1)	DK0800536T3 (no)
ES (1)	ES2277336T3 (no)
FI (1)	FI119374B (no)
HU (1)	HU222992B1 (no)
LU (1)	LU92912I2 (no)
MX (1)	MX9704779A (no)
NL (1)	NL300787I2 (no)
NO (2)	NO324181B1 (no)
NZ (1)	NZ301916A (no)
PL (1)	PL194312B1 (no)
WO (1)	WO1996021000A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2601882T5 (es) *	1999-04-09	2021-06-07	Kyowa Kirin Co Ltd	Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
SI1527100T1 (sl) *	2002-03-29	2009-12-31	Schering Corp	Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo
WO2003084569A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Drug containing antibody composition
US20070219117A1 (en) *	2003-10-27	2007-09-20	Medvet Science Pty Ltd	Bidentate motif and methods of use
JP4954709B2 (ja) *	2004-10-28	2012-06-20	協和発酵キリン株式会社	子宮内膜症治療剤
DK2152290T3 (da)	2007-04-30	2014-08-18	Glaxosmithkline Llc	Fremgangsmåder til indgivelse af anti-il-5-antistoffer
JP4335286B2 (ja)	2008-02-08	2009-09-30	ファナック株式会社	部品保護機能を備えたロボット制御装置及びロボット制御方法
US9834600B2 (en)	2008-03-28	2017-12-05	Glaxosmithkline Llc	Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody
EP2528947A4 (en) *	2010-01-28	2013-09-18	Glaxo Group Ltd	CD127 BINDING PROTEINS
JP6147670B2 (ja)	2010-12-22	2017-06-14	テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド	改善された半減期を有する修飾された抗体
EP3341409A1 (en)	2015-08-24	2018-07-04	Glaxosmithkline Intellectual Property (No. 2) Limited	Biopharmaceutical compositions
CN109195990A (zh) *	2016-03-30	2019-01-11	Musc研究发展基金会	通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
NZ754606A (en) *	2016-12-23	2023-06-30	Cephalon Llc	Anti-il-5 antibodies
CA3064522A1 (en)	2017-05-26	2018-11-29	Glaxosmithkline Intellectual Property Development Limited	Biopharmaceutical compositions and related methods
CA3076941A1 (en)	2017-09-29	2019-04-04	Jiangsu Hengrui Medicine Co., Ltd.	Il-5 antibody, antigen binding fragment thereof, and medical application therefor
CN109942706A (zh) *	2017-12-21	2019-06-28	三生国健药业（上海）股份有限公司	结合人il-5的单克隆抗体、其制备方法和用途
US20220010008A1 (en) *	2018-12-12	2022-01-13	Shanghai Pharmaexplorer Co., Ltd.	Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
CN113507938B (zh) *	2019-03-29	2024-04-16	广东恒瑞医药有限公司	包含抗il-5抗体的药物组合物及其用途
US20250230251A1 (en)	2023-12-20	2025-07-17	Bristol-Myers Squibb Company	Antibodies targeting il-18 receptor beta (il-18rb) and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8800397D0 (en) *	1988-01-08	1988-02-10	Sandoz Ltd	Improvements in/relating to organic compounds
US5096704A (en) *	1988-11-03	1992-03-17	Schering Corporation	Method of treating eosinophilia
JPH07563B2 (ja) *	1988-11-03	1995-01-11	シェリング・コーポレーション	好酸球増加症の予防または鎮静用薬剤
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA929328B (en) *	1991-12-02	1993-07-20	Fluor Corp	Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
EP0625201A1 (en) *	1992-02-06	1994-11-23	Schering Corporation	Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) *	1992-11-05	1994-05-24	Chemo Sero Therapeut Res Inst	モノクローナル抗体
AU1289795A (en) *	1993-11-19	1995-06-06	Baylor College Of Medicine	Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) *	1999-08-19	2001-02-22	Smithkline Beecham Corporation	Sialoadhesin factor-1 agonist and antagonist antibodies

1995
- 1995-12-22 ES ES95944692T patent/ES2277336T3/es not_active Expired - Lifetime
- 1995-12-22 AT AT95944692T patent/ATE346867T1/de active
- 1995-12-22 MX MX9704779A patent/MX9704779A/es unknown
- 1995-12-22 WO PCT/US1995/017082 patent/WO1996021000A2/en not_active Ceased
- 1995-12-22 EP EP95944692A patent/EP0800536B1/en not_active Expired - Lifetime
- 1995-12-22 NZ NZ301916A patent/NZ301916A/xx not_active IP Right Cessation
- 1995-12-22 CN CNB951977016A patent/CN100391977C/zh not_active Expired - Lifetime
- 1995-12-22 BR BRPI9510499-2A patent/BR9510499B1/pt active IP Right Grant
- 1995-12-22 DE DE69535319T patent/DE69535319T2/de not_active Expired - Lifetime
- 1995-12-22 CA CA002208503A patent/CA2208503C/en not_active Expired - Lifetime
- 1995-12-22 PL PL95321088A patent/PL194312B1/pl unknown
- 1995-12-22 DK DK95944692T patent/DK0800536T3/da active
- 1995-12-22 US US08/637,647 patent/US6129913A/en not_active Expired - Lifetime
- 1995-12-22 CZ CZ0196397A patent/CZ297045B6/cs not_active IP Right Cessation
- 1995-12-22 AU AU47450/96A patent/AU708951B2/en not_active Expired
- 1995-12-22 JP JP52118996A patent/JP2001523083A/ja not_active Withdrawn
- 1995-12-22 HU HU9901120A patent/HU222992B1/hu active Protection Beyond IP Right Term
1997
- 1997-06-20 NO NO19972913A patent/NO324181B1/no not_active IP Right Cessation
- 1997-06-23 FI FI972703A patent/FI119374B/fi not_active IP Right Cessation
2007
- 2007-10-16 JP JP2007269236A patent/JP2008029355A/ja not_active Withdrawn
2015
- 2015-12-16 LU LU92912C patent/LU92912I2/xx unknown
- 2015-12-18 NL NL300787C patent/NL300787I2/nl unknown
- 2015-12-18 NO NO2015027C patent/NO2015027I2/no unknown

Also Published As

Publication number	Publication date
NO2015027I1 (no)	2015-12-18
NZ301916A (en)	1999-05-28
LU92912I2 (fr)	2016-02-16
CN100391977C (zh)	2008-06-04
NO324181B1 (no)	2007-09-03
AU4745096A (en)	1996-07-24
FI972703L (fi)	1997-08-22
CA2208503A1 (en)	1996-07-11
BR9510499B1 (pt)	2009-05-05
NO2015027I2 (no)	2016-01-04
EP0800536B1 (en)	2006-11-29
CZ196397A3 (en)	1997-10-15
FI972703A0 (fi)	1997-06-23
JP2008029355A (ja)	2008-02-14
NL300787I1 (no)	2016-04-05
US6129913A (en)	2000-10-10
DK0800536T3 (da)	2007-04-02
ATE346867T1 (de)	2006-12-15
NO972913D0 (no)	1997-06-20
PL194312B1 (pl)	2007-05-31
JP2001523083A (ja)	2001-11-20
HUT78055A (hu)	1999-07-28
DE69535319D1 (de)	2007-01-11
DE69535319T2 (de)	2007-07-19
PL321088A1 (en)	1997-11-24
EP0800536A4 (en)	2004-12-01
AU708951B2 (en)	1999-08-19
WO1996021000A2 (en)	1996-07-11
BR9510499A (pt)	1999-03-30
FI119374B (fi)	2008-10-31
NL300787I2 (no)	2016-04-05
ES2277336T3 (es)	2007-07-01
MX9704779A (es)	1997-09-30
CZ297045B6 (cs)	2006-08-16
CN1175263A (zh)	1998-03-04
WO1996021000A3 (en)	1996-09-06
EP0800536A2 (en)	1997-10-15
CA2208503C (en)	2009-12-01
HK1003651A1 (en)	1998-11-06
HU222992B1 (hu)	2004-01-28

Publication	Publication Date	Title
NO972913L (no)	1997-08-19	Rekombinante IL-5 antagonister anvendelige ved behandling av IL-5 betingete forstyrrelser
BR0008688A (pt)	2002-01-08	Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP1749840A3 (en)	2008-10-15	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
SE9604793D0 (sv)	1996-12-20	New polymorphs
GB9619691D0 (en)	1996-11-06	Antibodies against E-selection
MX9704030A (es)	1998-02-28	1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
IL113941A (en)	2000-02-17	Perfluoroalkyl ketone inhibitors of elastase processes for making the same and pharmaceutical compositions containing them
GR3030371T3 (en)	1999-09-30	Triazole compounds and their use as dopamine-d 3?-ligands
PT758241E (pt)	2002-10-31	Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
DE69738613D1 (de)	2008-05-15	Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
ATE226947T1 (de)	2002-11-15	2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
DE69911401D1 (en)	2003-10-23	Immunoregulator
GB8900812D0 (en)	1989-03-08	Pharmaceutical method and compositions
SG48816A1 (en)	1998-05-18	Gonococcal anti-idiotypic antibodies and methods and compositions using them
DE69120287D1 (en)	1996-07-18	Aminosulfonylharnstoff-acat-inhibitoren
ATE238990T1 (de)	2003-05-15	Pyridylthioverbindungen zur bekämpfung von helicobacter-bakterien
PT751774E (pt)	2003-11-28	Derivados de dissulfureto de mercaptoacetilamida hipocolesterolemicos

Legal Events

Date	Code	Title	Description
2015-12-14	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: GLAXOSMITHKLINE LLC, US
2016-01-04	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: NUCALA - MEPOLIZUMAB; NAT. REG. NO/DATE: OPPGITT 20151218; FIRST REG. NO/DATE: EU/1/15/1043 20151202 Spc suppl protection certif: 2015027 Filing date: 20151218
2016-01-11	MK1K	Patent expired
2018-01-08	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: MEPOLIZUMAB; REG. NO/DATE: EU/1/15/1043 20151218 Spc suppl protection certif: 2015027 Filing date: 20151218 Extension date: 20201222
2018-10-15	SPCE	Application to extend a supplementary protection certificate (spc)	Free format text: PRODUCT NAME: MEPOLIZUMAB; REG. NO/DATE: EU/1/15/1043 20151202 Spc suppl protection certif: 2018035 Filing date: 20181004
2019-05-27	SPCH	Extension of a supplementary protection certificate (spc) granted	Free format text: PRODUCT NAME: MEPOLIZUMAB; REG. NO/DATE: EU/1/15/1043 20151202 Spc suppl protection certif: 2018035 Filing date: 20181004 Extension date: 20210622
2021-01-11	SPCX	Expiry of an spc	Free format text: PRODUCT NAME: MEPOLIZUMAB Spc suppl protection certif: 2015027